LY518674 是一种高效、选择性的PPARα拮抗剂，对人PPARα 作用的EC50值为 42 nM。它能降低甘油三酸酯，增加 HDL-C，可用于研究动脉粥样硬化。

LY518674 decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis. LY518674 is an effective and selective PPARα antagonist (EC50: 42 nM for human PPARα).

LY518674 decreases triglycerides and increased HDL-C in vivo[2]. LY518674 significantly enhances apolipoprotein A-I (apoA-I) turnover without a major impact on steady-state levels of apoA-I or high-density lipoprotein-cholesterol (HDL-C) [3].

425671-29-0

C23H27N3O4

409.48

LY-674

DMSO:250 mg/mL (610.53 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years